Viewing data from:

KETAMINE HYDROCHLORIDE

ANDA

KETAMINE HYDROCHLORIDE | A215808 | FRESENIUS KABI USA LLC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: KETALAR(TE code: AP)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$1.55

per ml

Lowest NADAC/Unit

$0.5397

per ml

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
65219018605KETAMINE 500 MG/5 ML VIAL	$1.55	ML	Generic	—	2026-06-17
65219018810KETAMINE 500 MG/10 ML VIAL	$0.5397	ML	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs (3 FSS)

Lowest Price

$39.26

Highest Price

$78.69

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
65219-0184-20KETAMINE HCL 10MG/ML INJ	$78.69	FSS	Fresenius Kabi, LLC	05/14/2030
65219-0186-05KETAMINE HCL 100MG/ML INJ	$51.66	FSS	Fresenius Kabi, LLC	05/14/2030
65219-0188-10KETAMINE HCL 50MG/ML INJ	$39.26	FSS	Fresenius Kabi, LLC	05/14/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain6 active DMFs2 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

CU CHEMIE UETIKON GMBHKETAMINE HYDROCHLORIDE

DMF 76861988

FINE ORGANICS LTDKETAMINE HYDROCHLORIDE

DMF 190822005

SUPRIYA LIFESCIENCE LTDKETAMINE HYDROCHLORIDE USP

DMF 279212014

AREVIPHARMA GMBHKETAMINE HYDROCHLORIDE

DMF 290942015

GLAND PHARMA LTDKETAMINE HYDROCHLORIDE

DMF 353852020

MAITHRI DRUGS PRIVATE LTDKETAMINE HYDROCHLORIDE USP

DMF 370142022

DEGUSSA AG WERK RADEBEULInactiveKETAMINE HYDROCHLORIDE

DMF 131411998

KAMUD DRUGS PVT LTDInactiveKETAMINE HYDROCHLORIDE USP

DMF 222562008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — EQ 10MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jan 13, 2023

No patent or exclusivity listings for this strength.

#002 — EQ 50MG BASE/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Jan 13, 2023

#003 — EQ 100MG BASE/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Apr 18, 2025